August 7, 2018

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

CytoSorbents Corporation (CTSO-NASDAQ)

CTSO: Q2 Product Sales Beat Big. More Upward Estimate Revisions. New Catalysts Come Online. Moving PT to $15/share

Based on our 10-year DCF model, which uses a 10% discount rate and a 2% terminal growth rate, the shares are valued at approximately $15.

Current Price (08/07/18)	$11.20
Valuation	**$15.00**

OUTLOOK

Q2 was a very strong quarter for product sales which set a new record high, jumping 18% from Q1 and almost 73% yoy. Product sales were also well ahead of our estimate and given the steeper than anticipated growth rate and new catalysts coming online, we have again made upward revisions to our forecasts. Germany remains the main market, accounting for 62% of product sales in Q2, although product sales in other countries also continues to grow. Product margin, at 74%, remains elevated and is expected to move higher following the impending opening of a new, higher capacity, manufacturing facility. These trends, in addition to improvement in operating loss, are expected to continue. Management continues to guide for operating income (ex non-cash and clinical trial expenses) to move into the black (for the first time) on a quarterly basis during 2018. CTSO has noted that they estimate this is achievable at a quarterly product revenue run-rate of approximately $5.5M - while we had previously forecasted Q4 sales of approximately $5.3M (i.e. $200k less than CTSO's op loss b/e revenue number), our upwardly revised estimates following the stronger than expected Q2 now puts our Q4 product sales number at almost $5.7M. Adjustments to our model, and more significantly a reduction to risk discount as a result of increased liquidity from entry into Russell indices, has moved our PT from $12 to $15/share.

SUMMARY DATA

52-Week High	**$13.40**
52-Week Low	**$4.50**
One-Year Return (%)	**143.68**
Beta	**0.14**
Average Daily Volume (sh)	**355,020**
Shares Outstanding (mil)	**31**
Market Capitalization ($mil)	**$352**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**13**
Insider Ownership (%)	**7**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**54.9**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2018 Estimate	**N/A**
P/E using 2019 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**Above Avg.,**
Type of Stock	**Small-Growth**
Industry	**Med Products**

ZACKS ESTIMATES

Revenue
(in '000 of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	3114 A	3566 A	3824 A	4647 A	15151 A
2018	4925 A	5755 A	5816 E	6213 E	22708 E
2019					32611 E
2020					44280 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	-0.05 A	-0.04 A	-0.07 A	-0.11 A	-0.32 A
2018	-0.10 A	-0.19 A	-0.10 E	-0.11 E	-0.50 E
2019					-0.28 E
2020					-0.13 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

Q2 2018 Update: *Product Sales Beat Big. More Upward Estimate Revisions As New Catalysts Come Online. …*

CytoSorbents reported financial results for their second quarter ending June 30th and provided a business update. Relative to the financials, it was a very strong quarter for product sales which set a new record high, jumping 18% from Q1 and almost 73% yoy. Product sales were also well ahead of our estimate and given the steeper than anticipated growth rate and new catalysts coming online, we have again made upward revisions to our forecasts. Germany remains the main market, accounting for 62% of product sales in Q2, although product sales in other countries also continues to grow. Product margin, at 74%, remains elevated and is expected to move higher following the impending opening of a new, higher capacity, manufacturing facility.

These trends, in addition to improvement in operating loss, are expected to continue. Management continues to guide for operating income (ex non-cash and clinical trial expenses) to move into the black (for the first time) on a quarterly basis during 2018. CTSO has noted that they estimate this is achievable at a quarterly product revenue run-rate of approximately $5.5M - while we had previously forecasted Q4 sales of approximately $5.3M (i.e. $200k less than CTSO's op loss b/e revenue number), our upwardly revised estimates following the stronger than expected Q2 now puts our Q4 product sales number at almost $5.7M.

Growth of the direct sales force, onboarding of additional third-party distribution and increased activity from CTSO's partners have all contributed to adoption and utilization of CytoSorb and the resultant product sales growth. So has increased use in a variety of indications. Importantly, management noted that they are seeing demand-pull from the market - indicating that awareness of CytoSorb over the last few years has reached a point where education in sales process has become easier. That trend, as we have noted in the past, will undoubtedly continue and benefit from continued increase in utilization (CytoSorb has now been used in more than 47k human treatments vs. 27 one-year prior), more reports of clinical successes and the awareness-related benefits of the ongoing REMOVE and REFRESH II clinical studies.

Much of the growth is coming from CTSO direct sales efforts. Headcount of the direct sales team increased by 75% since early 2017 and resulted in direct product sales growing 82% yoy through the first half of 2018. Direct sales accounted for 76% of product sales in 1H 2018, up from 72% in the prior year – the proportional increase in direct sales likely contributed to the ~750 basis point widening in product margin over the same period.

As we have stated in recent prior updates, while we reiterate the potential for short-term volatility in product sales, we think the additional history of regular growth should provide ever-increasing confidence of the robustness of the fundamentals of the source and 'quality' of these revenues in the context of long-term prospects. Re-orders from existing customers, initial orders from new customers, accounts and territories, use of CytoSorb for additional indications and ramping utilization numbers are all common themes that management cites in relation to the source of product sales growth. Bulk orders and inventory-stocking are not.

We continue to like near and long-term prospects for product sales growth, the latter particularly so in the context of potential eventual entry into the U.S. market as well as other potential catalysts that have yet to make any impact. Among the latter are new product launches, such as HemoDefend (U.S. FDA trial anticipated to begin early-2019), label expansion (including recently for OUS use in bilirubin and myoglobin removal) and potential new partnerships and government grants.

Financials…

Q2 total revenue was $5.8M, up 61% yoy and 17% sequentially. Product revenue was $5.3M (vs. $4.8M E), up 73% yoy and +18% from Q1 '18. Grant income remains robust and was $509k (vs $529k E) in Q2. While we expect additional (and near-term) opportunities to score future grants, the yet-to-be billed portion of CTSO's current grant contracts is still significant. Of the remaining ~$2.2M available under their current roster, we model ~$1.1M to be billed during this year (and most of the remainder in 2019).

Relative to product sales, much of the recent growth has been attributed to improved reimbursement in Germany. And while Germany has been a significant contributor to revenue, that market may still remain relatively untapped given their significant population and large hospital network. Management has indicated that adoption in that country has been brisk and aided by strong support by certain KOLs. One hospital in Germany already generates over $1M in product sales for CTSO. With over 400 mid-to-large hospitals in the country, we think there is considerable near-term upside from that market.

Expansion of the geographic and distribution footprint as well as increasing commercial use in a growing number of 'indications' have also benefitted product revenue. In July CTSO's announced distribution to several more countries, bringing the total to 53 countries. CytoSorb has been used for a host of conditions in commercial clinical practice and clinical studies, including more than 60 investigator-initiated studies. The new indication for removal of bilirubin and myoglobin could have the effect of further expanding use. While CE Mark meant that clinicians had wide discretion in what conditions to employ CytoSorb, this new label expansion adds credence for use in these specific indications. Additionally, per management's comments on the Q2 call, there is a reimbursement benefit related to on-label (as opposed to, previous, off-label) use for these conditions.

Meanwhile, grant income continues to help subsidize R&D as well as providing additional validation of CTSO's technology (particularly given the list of contracts has continually grown). The recent label expansion of CytoSorb for the removal of myoglobin, for example, appears to be a direct extension of the rhabdomyolysis clinical study funded by a grant from the USAF. We think CTSO will continue to look to monetize the successes of these grant-funded studies with further label extensions and in the development of new technologies (such as HemoDefend). That could provide additional optionality in terms of commercial programs that CTSO could pursue and, potentially, with the consummation of additional commercialization partnerships.

The last three most recent grant awards are funded by the United States Army Medical Research Acquisition Activity (USAMRAA), including two in May and one in September 2017. This includes funding of up to $999k over two years ($519k of which has been paid to-date) for a phase II contract related to the development of HemoDefend in enabling universal plasma. The other one awarded in May is a phase I contract which will pay up to $719k over four years ($143k of which has been paid to-date) and relates to novel hemoadsorptive therapies for severe burn injuries. Then in September '17 a phase II SBIR contract worth up to $1M over 29 months ($168k paid to-date) was awarded – this relates to the development of potassium binding sorbents to be used in the treatment of traumatic injury and acute kidney injury – this contract follows the related phase I grant that CTSO scored in July 2016.

Product margin, at 74% was up from 65% in Q2 '17, flat from Q1 of this year and second best in history. Product margin continues to come in ahead of what we had anticipated - we have made some upward adjustments to product margin estimates following Q2 results. While production volumes (in addition to direct vs distributor sales mix, pricing increases and certain non-manufacturing efficiencies) have already contributed to widening of product margins (which have expanded 600 basis points over the last two years), the impending opening of a new manufacturing facility is expected to create even greater economies of scale. The facility, which has production capacity to handle ~$80M worth of product sales, came online in Q2 and is expected to account for all of CTSO's production by the end of this month. Product margins, which management continues to guide to eventually eclipse 80%, are expected to benefit immediately following commencement of production at this new site.

Operating expenses were $8.2M in the most recent period and up considerably from both Q2 '17 ($4.4M) and Q1 '18 ($6.5M). However, excluding stock compensation (which can increase when the stock price rises), which was almost $2.1M in the most recent quarter (vs. ~$800k in Q2 '17 and $500k in Q1 '18), the increases are more muted. In fact, on a % of product sales basis, operating expenses ex-stock comp in Q2 '18 (116%) was lower than both comparable periods (Q2 '17: 119%, Q1 '18: 134%). The comparisons and metrics are meaningful, in our opinion, particularly in the context of the viability of management achieving their guidance of reaching a point of operating income break-even (as defined earlier) in the very near term.

R&D expense through the first half of 2018 is 2.5x that of the prior-year period - with much of the increase related to REFRESH II activities. We model R&D expense to steepen again with anticipation of ramping REFRESH 2 enrollment.

Cash used in operating activities was $3.3M and $5.5M ($2.3M and $5.0M, ex-changes in working capital) in the three and six months ending 6/30/18, compared to $1.9M and $3.9M ($1.6M and $3.1M, ex-changes in working capital) in the comparable prior-year periods. Cash balance was just over $25M at Q2 '18 quarter end. In March CTSO restructured terms of their $10M loan (principal of which would have begun to amortize), which is interest-only for 18 months (or for 24 months upon drawing the available $5M "B" tranche) – this will provide a little bit more runway and, per our estimates, get CTSO to at (or nearly at) a point of GAAP operating profitability by the time principal begins payback.

Operational Update: New Liver Disease Indication, REFRESH 2 Protocol Update, REMOVE Ramping Enrollment, HemoDefend FDA Program...

European Approval for Treatment of Liver Disease and Trauma
Organ failure has recently become a significant focus for CTSO and new indications are directly aligned with that goal. In mid-May CTSO announced CytoSorb received European approval for use in the reduction from the blood of elevated bilirubin and myoglobin. Elevated bilirubin is associated with chronic liver disease and failure, while elevated myoglobin, which is a symptom of severe trauma, can lead to kidney failure. While CE Mark has always meant that (at least in theory) clinicians (in areas of the world where CE Mark is accepted) had wide discretion to use CytoSorb as they saw fit (mostly for conditions in which cytokines are elevated), we think that this new approval likely does expand the overall market for the device.

Bilirubin is a by-product from the breakdown of hemoglobin. Normally, bilirubin is conjugated (i.e. processed) by the liver and then excreted. But, in people with liver disease, the liver has difficulty processing bilirubin, resulting in a toxic build-up of the substance. Elevated bilirubin is common among people with hepatitis A, alcoholism and non-alcoholic fatty liver disease (NASH) - a global market estimated at approximately 50M people.

Myoglobin, found in heart and skeletal muscles, is tasked with capturing oxygen which muscles then use for energy. But, when the body experiences trauma, myoglobin (and other substances) is released into the blood and can become elevated (i.e. rhabdomyolysis). High levels of myoglobin can be toxic - it is the kidney's job to remove it from the blood so it can be excreted in the urine. Typical treatment consists of intravenous fluids and extracorporeal therapy (i.e. dialysis). As a reminder, CytoSorb was evaluated in a clinical study funded by a grant from the U.S. military for the removal of myoglobin in patients with rhabdomyolysis. It has also been the subject of case studies for rhabdomyolysis.

These new indications mean that clinicians can use CytoSorb on-label for conditions associated with elevated cytokines, myoglobin and bilirubin. 'On-label' potentially opens up use in instances where institutional policies forbid off-label use and, per management's comments on the call, may provide reimbursement benefits. And while not mentioned specifically by CTSO, we think that having approval may also open the door to one or more commercialization partnerships focused on these indications (perhaps similar to CTSO's deal with Fresenius).

CytoSorbents believes these new indications have the potential to significantly increase the total worldwide market for their device - while we think it is too early to estimate the significance of these approvals, we think they likely do broaden the market for CytoSorb (for the reasons stated) and, perhaps more importantly, provide additional strategic options. We also think it may be a harbinger of more approvals to come - clearly CTSO has already parlayed validation from grant-funded studies into broadening the commercial market for CytoSorb - that may be a strategy that they continue to employ.

REFRESH 2 enrollment commences, although slower than expected
As a reminder, REFRESH 2 is expected to be a pivotal FDA registration study and provide primary support for a U.S. regulatory filing for use of CytoSorb during cardiac surgery. In December 2017 FDA approved the IDE. CMS approval was also required and obtained, as was central ethics committee approval. Per comments on the Q2 call (August 2nd), seven sites are actively recruiting, three more have concluded clinical trial agreements and 19 others are completing start-up activities.

As we noted in recent updates, the pace of onboarding study sites had been slower than anticipated - which hampered enrollment. The first patient was enrolled in March - but clearly there has been a headwind to increasing the pace of enrollment. CTSO had previously mentioned that part of the hold up was legacy REFRESH I sites requesting the full IDE protocol – given the similarities in the studies, the extent of the administrative boxes that needed to be checked for these sites was underestimated. And while management was hesitant to offer specifics in terms of their expectations for site onboarding, the message was (at that time) that it should begin to accelerate.

While enrollment-to-date was not disclosed on the Q2 call, clearly the message is that it is less than hoped-for. So, a protocol amendment (one that is backward compatible for patients already in the study) was submitted to FDA for approval. Complete specifics of the amendment were not publicly disclosed - although apparently it does include an increase in the age limit and modifications to baseline renal risk factors. More importantly, management indicated that it will facilitate enrollment and increase the target market (if approved) - with no compromise to any other aspects.

We hope to know more about the amendment when approved by FDA - which CTSO expects sometime in Q3. CTSO hopes to have 15 to 20 sites ready to enroll when that happens. At that time, they expect the pace of

enrollment to be approximately one patient per site per month. Which implies full enrollment (n=400) by approximately September 2020. Meanwhile, since the amendment is backward-compatible, the study can continue to enroll based on the initial protocol.

REFRESH II design

The multi-center, randomized, controlled U.S. study is expected to enroll up to 400 patients (over two years) which are undergoing elective open heart surgery for valve replacement or aortic reconstruction with hypothermic cardiac arrest. Patients will be randomized to either standard-of-care (i.e. control) or standard-of-care plus dual CytoSorb cartridges (in parallel in a heart-lung bypass circuit). The primary endpoint, reduction of acute kidney injury (AKI), is outcomes-based. AKI will be measured by Kidney Disease Improving Global Outcomes (KDIGO) criteria. Secondary endpoints include time on mechanical ventilation, use of vasopressors, days in ICU, reduction of inflammatory mediators and 30-day mortality.

Relative to the KDGIO criteria primary endpoint, this is what we found based on our own research…published in March 2012, KDIGO guidelines are an international initiative for the evaluation and management of AKI. KDIGO guidelines build on already established AKI measures such as RIFLE (Risk, Injury, Failure, Loss of Kidney Function, and End-stage Kidney Disease) and AKIN (Acute Kidney Injury Network) criteria and measure changes in serum creatinine as well as urine output in staging AKI (i.e. 1 – 3 severity scale). Below is the definition and staging of AKI as per KDIGO guidelines (SOURCE: Kidney International Supplements, KDIGO Clinical Practice Guideline for Acute Kidney Injury. Vol 2, Issue 1, March 2012).

KDIGO Definition of AKI

AKI is defined as any of the following (*Not Graded*):

- Increase in SCr by ⩾0.3 mg/dl (⩾26.5 μmol/l) within 48 hours; or
- Increase in SCr to ⩾1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
- Urine volume <0.5 ml/kg/h for 6 hours.

KDIGO AKI Staging

Stage	Serum creatinine	Urine output
1	1.5–1.9 times baseline OR ⩾0.3 mg/dl (⩾26.5 μmol/l) increase	<0.5 ml/kg/h for 6–12 hours
2	2.0–2.9 times baseline	<0.5 ml/kg/h for ⩾12 hours
3	3.0 times baseline OR Increase in serum creatinine to ⩾4.0 mg/dl (⩾353.6 μmol/l) OR Initiation of renal replacement therapy OR, In patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m^2	<0.3 ml/kg/h for ⩾24 hours OR Anuria for ⩾12 hours

Despite the newness of the KDIGO criteria, it appears to be largely widely accepted in the U.S. for defining AKI[1]. In addition, clinical studies[2] have demonstrated a significant positive correlation between KDIGO AKI stage and 30-day mortality, including among subjects undergoing cardiac surgery[3].

Based on feedback and comments from management, REFRESH 2 was designed in such a way to increase odds of reaching statistical significance on the primary endpoint. Specifically, by enriching with a population at already relatively high risk of AKI (i.e. those already predisposed to known risk factors), it heightens odds that valve replacement surgery (which is well documented as a cause of AKI) will result in AKI. Obviously, the goal is to demonstrate significantly fewer CytoSorb patients develop AKI versus control (i.e. SOC). The proposed protocol amendment includes a modification to baseline risk factors - which may mean the patient population is not quite as narrow as initially designed.

[1] Palevsky PM, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013 May;61(5):649-72. doi: 10.1053/j.ajkd.2013.02.349. Epub 2013 Mar 15.

[2] Talito Machado Levi, et al. Comparison of the RIFLE, AKIN and KDIGO criteria to predict mortality in critically ill patients. Rev Bras Ter Intensiva. 2013 Oct-Dec; 25(4): 290–296.

[3] Maurício Nassau Machado, et al. Acute kidney injury based on KDIGO (Kidney Disease Improving Global Outcomes) criteria in patients with elevated baseline serum creatinine undergoing cardiac surgery. Rev Bras Cir Cardiovasc. 2014 Jul-Sep; 29(3): 299–307.

And while enriching with a narrower patient population may similarly narrow the label if and when FDA cleared (again, the protocol amendment was designed to increase the defined patient population, which also broadens the indicated-use population, if approved), we think that the main focus should first be on hitting singles – that is, get CytoSorb approved for marketing in the U.S. for a "usable" indication (such as this) and expand the label thereafter. The initial indication would also be another significant step towards demonstrating safety (and build on that from REFRESH I as well as from the 40k+ human uses overseas) – which could help in facilitating off-label use as well as provide support for approval of future FDA studies in other indications (potentially such as for sepsis or infective endocarditis – below). And in the meantime, OUS product sales may immediately benefit as a result of implied or presumed clinical legitimacy associated with FDA approving the IDE – which can sometimes result in a halo effect and prompt use in the related indication.

40 Pts Already Enrolled in German Infective Endocarditis RCT. Follows Recent Published Study Demonstrating CytoSorb's Utility in I.E.

As a reminder, a manuscript of a retrospective case series involving 39 patients with infective endocarditis undergoing valve replacement surgery using CytoSorb was published in May 2017 in the International Journal of Artificial Organs. The study (which was the largest study to-date using CytoSorb for patients with infective endocarditis undergoing valve replacement surgery) showed that intraoperative use of CytoSorb was associated with lower mortality as compared to historical data (without CytoSorb use) as well as a meaningful reduction in certain inflammatory mediators (including IL-6 and IL-8), hemodynamic stabilization and reduction in vasopressor requirements. (See our Appendix for our discussion of this case report).

Infective endocarditis, as the name implies, is an infection of the endocardial surface of the heart – which includes one or more heart valves. It is a result of certain bacteria and other pathogens that enter the bloodstream, which can be highly and rapidly destructive to heart valves and spread to systemic sepsis and septic shock. Septic shock occurs when infection leads to critically low blood pressure and organ failure. Rates of infective endocarditis have been on the rise as a result of the recent dramatic growth of intravenous (i.e. dirty needles) heroin use in the U.S.).

CTSO hopes to further validate use of CytoSorb in this patient population and in December 2017 announced that a new, large, randomized clinical study, conducted in Germany, is aimed at doing just that. The multi-center study, dubbed **REMOVE (REvealing Mechanisms and Investigating Efficacy Of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis) has already enrolled 40 patients (of an expected 250 total).** REMOVE will evaluate safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery. Primary endpoint is the difference in mean SOFA (Sequential Organ Failure Assessment) scores between experimental and control arms. Secondary endpoints include 30-day mortality, changes in cytokine levels, need for supportive care therapies such as vasopressors, mechanical ventilation, and dialysis, incidence of stroke, and the length of intensive care unit and in-hospital stay.

This study could be a win-win for CytoSorbents – potentially providing robust evidence of CytoSorb's utility in a large and growing patient population – and doing so at little or no cost to the company as the study is being fully funded by the German government. Jena University Hospital is primary sponsor - Jena has been an important partner of CTSO's over the years and manages the company's International CytoSorb registry. B.R.A.H.M.S. (a division of Thermo Fisher Scientific) and the Fraunhofer Institute for Interfacial Engineering and Biotechnology are co-collaborators.

REMOVE incorporates inclusion criteria of EuroSCORE II ≥ 4. Higher EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) scores are associated with higher risk of mortality. For reference, mean and median EuroSCORE II scores among the 39 patients from the earlier case study was 12.8 and 26.0, respectively, - so those were relatively very sick individuals. While a specific organ function-related measure was not part of that case study, certain parameters associated with organ function and clinical outcomes, were. The case study showed that CytoSorb-treated patients experienced marked reduction in IL-6 and IL-8, "normalization of lactate and base excess back to preoperative baseline levels within 3 days and hemodynamic stability before, during, and after the operation accompanied by a rapid decrease in need for vasopressors."

Primary endpoint of REMOVE is change in SOFA score – which is a widely accepted clinical measure of organ function as well as of mortality. SOFA is based on six different measures; respiratory, cardiovascular, hepatic, coagulation, renal and neurological – many of which were assessed (with favorable results) in the 39-patient case study (see Appendix). Mortality was also much lower than predicted in the 39-patient case series – also suggesting a CytoSorb-related mortality benefit. We also note that another recently published study ("Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study", *Journal of Artificial Organs*, Sept 2017) also showed that CytoSorb treatment was associated with significant reduction in vasopressor

requirements, hemodynamic stability, pro-inflammatory mediators and mortality. We provide this as background as we think it offers context in terms of the potential for eventual success of REMOVE.

REMOVE is being conducted in parallel with REFRESH II, which specifically excludes subjects with infective endocarditis. As such and assuming success of both studies, CytoSorbents envisions that their device could one day be considered standard of care for the majority of open heart valve replacement surgeries ("hundreds of thousands of procedures worldwide"). Management recently noted that, given the robustness of the trial design, that it might be possible to use it as primary support (assuming positive results) for a future FDA filing for an infective endocarditis indication.

While it is way too early to guess the chances of that happening, positive results from this German study would certainly lend significant veracity to the likelihood of an eventual FDA approval for a similar indication – whether it requires a U.S study or not. But, it's probably no coincidence that the anticipated timelines for REMOVE and REFRESH II are similar – both of which are commencing now and with expected durations of two years.

HemoDefend

Since 2015, HemoDefend has been the subject of a $1.52M phase II SBIR grant funded by NHLBI (part of NIH) and U.S. Special Operations Command. The focus of the work (per CTSO's PR) is to, "help advance the Company's HemoDefend™ blood purification technology towards commercialization for the purification of packed red blood cell (pRBC) transfusions. That contract followed the successful completion of a phase I SBIR contract which was, "designed to bring the HemoDefend™ in-line blood filter to human testing, a required major step towards commercialization. In addition, the contract will also fund development of new polymers that could enable safer whole blood transfusions, a potentially life-saving advance in the treatment of trauma and military combat casualty victims."

Approximately $140k remains under the phase II contract but CTSO is wasting no time in readying for the subsequent steps towards a goal of commercialization. Management noted on the Q2 call that they expect to have a clinical trial-ready HemoDefend device ready for evaluation by the end of August. If all goes well they hope to begin a U.S. study aimed at supporting an eventual FDA filing started by Q1 2019. In the meantime, they expect to be building clinical trial devices later this year.

The anticipated use of HemoDefend for this application is, per CTSO's description, "a point of transfusion inline filter focused on reducing non-infectious contaminants that can cause transfusion reactions ranging from relatively mild fever and allergic reactions to very severe transfusion related acute lung injury which is the leading reported cause of transfusion related deaths that occurs in roughly 1 in 1k to 1 in 5k transfusions."

Near-term Outlook

We continue to see no reason why product sales do not continue to set new regular records, particularly given some recent catalysts that came online. These include;

- **dedicated reimbursement in Germany** which became effective Jan 1, 2017. While the new code may have actually been an impediment to sales in early 2017, indications (including rates increasing by as much as 100% in some locations as well as feedback from some of CTSO's key German accounts) are that the reimbursement issue is proving to be just a short-term hiccup. Certainly the fact that product revenue grew 49% from 1H 2017 to 1H 2018, also supports that theme. If reimbursement expands to other parts of Europe, that would likely provide additional upside

- expanded indications: removal of bilirubin and myoglobin came in May 2018. Should provide some level of market expansion and, potentially provide strategic optionality. We also think it may be a harbinger of more approvals to come - clearly CTSO has already parlayed validation from grant-funded studies into broadening the commercial market for CytoSorb - that may be a strategy that they continue to employ

- demand-pull: management noted that they are seeing demand-pull from the market - indicating that awareness of CytoSorb over the last few years has reached a point where education in sales process has become easier. That trend, as we have noted in the past, will undoubtedly continue and benefit from continued increase in utilization

- **accelerating adoption in Germany**, the largest (yet still barely tapped) medical device market in Europe. One hospital in Germany already generates over $1M in product sales for CTSO. With over 400 mid-to-large hospitals in the country and strong support from KOLs, we think there is considerable near-term upside from that market.

- **Fresenius**: roll-out began in Q2 2016, expect this to continue to expand over time. In addition, co-marketing

agreement, which began initial roll-out in Q3 2017 (in 1st 6 countries) continues to expand. This will greatly expand FMS's footprint

- **Terumo** (cardiac channel): launch began December 2016. We think Terumo could also be key in eventually accessing (very substantial) Japanese market

- **Biocon**: CTSO's large distributor in India recently reorganized CytoSorb into a separate division. Biocon has been a key partner and this restructuring is an indication they are putting even more resources behind CytoSorb. In February 2018 CTSO announced that Biocon will also handle distribution in Malaysia. Biocon could be key in driving additional adoption and use in investigator initiated studies.

- **direct sales force**: growth in size of the direct sales force has benefitted product sales growth and product margins. Headcount of the direct sales team increased by 75% since early 2017. Product sales increased by more than 100% and gross margins widened by 600 bps over the same period

- **distribution/geographic expansion**: distribution now secured in 53 countries and we expect additional territories and distribution agreements will continue to come online on a regular basis

- **clinical data / validation**: has been and continues to be the driving force behind adoption. In addition to REFRESH and REMOVE, a fairly regular flow of clinical data from case studies and investigator-initiated trials should continue. FDA IDE approval can sometimes have somewhat of a halo effect – prompting use in the related indication overseas. CytoSorb has now been used in more than 46k human treatments – up from 27k ~12 months ago

- **increasing use in a number of critical care applications** where CytoSorb has been associated with positive patient outcomes including sepsis. Management has indicated that sepsis remains on their radar

- **ECMO kit launch**: provides seamless and rapid connection of CytoSorb to extracorporeal membrane oxygenation

- **increased capacity**: a new manufacturing facility, which is expected to increase capacity to support up to $80M in sales, is expected to come online in August 2018 and immediately benefit margins

Valuation

We expect to see continued strength in product sales growth through 2018, as well as more strides on the operational front. We see several catalysts that begin to make either an initial or a greater impact over the next 18 - 24 months. Among the former are new product launches, such as HemoDefend , label expansion (including recently for OUS use in bilirubin and myoglobin removal) and potential new partnerships and government grants. Among the latter are dedicated reimbursement in Germany and accelerating adoption in that country, greater contribution from Fresenius (including from co-marketing agreement) as well as from Terumo (which came online in December 2016), maturation of existing distribution relationships and expansion of the overall sales footprint, and the release of additional clinical data supporting the utility of CytoSorb in a several indications.

We have made some upward adjustments to our revenue estimates following Q2 results. We now look for 2018 and 2019 product and total revenue of $20.6M (+54%) / $22.7M (+50%) and $31.4M (+52%) / $32.6M (+44%), revised from $19.6M / $21.7M and $30.5M / $31.7M.

We continue to show CTSO nearly reaching GAAP full-year operating profitability in our out-year (2020). And while our model may be slightly conservative, we also continue to believe management's guidance of reaching a level of break-even operating profitability (excluding clinical trial-related and non-cash expenses) on a quarterly basis in 2018 is also achievable.

The addition of CTSO to the Russell 2000 and Russell 3000 indices in late-June provides more liquidity in the stock, which we treat as a reduction to our risk discount - which we have moved from 13% to 10%. The updates to our model, and more significantly, the update to our risk-discount has moved our 10-year DCF-based valuation from $12 to $15/share.

FINANCIAL MODEL

CytoSorbents Inc.

	2017 A	Q1A	Q2A	Q3E	Q4E	2018 E	2019 E	2020 E
CytoSorb Sales	$13,381.9	$4,433.3	$5,245.6	$5,269.0	$5,682.5	$20,630.4	$31,404.0	$43,520.0
y-o-y growth	63.1%	70.8%	72.5%	52.8%	32.3%	54.2%	52.2%	38.6%
Total Royalties/Grants/Other	$1,769.7	$491.4	$509.9	$547.0	$530.0	$2,077.4	$1,207.0	$760.0
y-o-y growth	33.9%	-5.0%	-2.9%	45.6%	51.1%	17.4%	-41.9%	-37.0%
Revenue	$15,150.8	$4,924.7	$5,755.4	$5,816.0	$6,212.5	$22,707.7	$32,611.0	$44,280.0
YOY Growth	59.0%	58.2%	61.4%	52.1%	33.7%	49.9%	43.6%	35.8%
Cost of Goods Sold	$5,518.4	$1,567.6	$1,785.9	$1,808.5	$1,814.3	$6,976.3	$8,248.9	$10,220.4
Gross Income	$9,632.4	$3,357.0	$3,969.6	$4,007.5	$4,398.2	$15,731.4	$24,362.1	$34,059.6
Gross Margin	63.6%	68.2%	69.0%	68.9%	70.8%	69.3%	74.7%	76.9%
SG&A	$15,558.7	$4,677.9	$6,581.7	$4,804.0	$5,224.0	$21,287.6	$24,008.4	$28,766.7
SG&A % of Prod Sales	116.3%	105.5%	125.5%	91.2%	91.9%	87.1%	76.5%	66.1%
R&D	$3,916.3	$1,780.3	$1,575.8	$1,955.0	$2,555.0	$7,866.1	$8,327.0	$8,518.0
R&D % Tot Sales	25.8%	36.2%	27.4%	33.6%	41.1%	34.6%	25.5%	19.2%
Operating Income	($9,842.6)	($3,101.2)	($4,187.9)	($2,751.5)	($3,380.8)	($13,422.3)	($7,973.2)	($3,225.1)
Operating Margin	-	-	-	-	-	-	-	-
Total Other Expense	($705.1)	($119.1)	$1,633.3	$250.2	$250.2	$2,014.6	$1,506.2	$1,318.6
Pre-Tax Income	($9,137.5)	($2,982.0)	($5,821.2)	($3,001.7)	($3,631.0)	($15,436.9)	($9,479.4)	($4,543.7)
Taxes (benefit)	($676.7)	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Tax Rate	7.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Preferred/Othr Dividend	$335.7	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Net Income	($8,796.5)	($2,982.0)	($5,821.2)	($3,001.7)	($3,631.0)	($15,436.9)	($9,479.4)	($4,543.7)
Net Margin	-58.1%	-60.6%	-101.1%	-51.6%	-58.4%	-68.0%	-29.1%	-10.3%
EPS	($0.32)	($0.10)	($0.19)	($0.10)	($0.11)	($0.50)	($0.28)	($0.13)
YOY Growth		-	-	-	-			
Diluted Shares O/S	27,614	29,351	30,302	31,500	32,000	30,788	34,000	35,000

Brian Marckx, CFA

Appendix: Summary of Recent Clinical Studies in Various Indications

Infective Endocarditis 30-Patient Case Series Published in Journal of Artificial Organs

A manuscript of a retrospective case series involving 39 patients with infective endocarditis undergoing valve replacement surgery using CytoSorb was published in May 2017 in the International Journal of Artificial Organs. *Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass - a case series*, was the largest study to-date using CytoSorb for this patient population in valve replacement surgery.

Infective endocarditis, as the name implies, is an infection of the endocardial surface of the heart – which includes one or more heart valves. Rates of infective endocarditis have been on the rise as a result of the recent dramatic growth of intravenous (i.e. dirty needles) heroin use in the U.S. These infections, from certain bacteria and other pathogens that enter the bloodstream, can be highly and rapidly destructive to heart valves and spread to systemic sepsis and septic shock. In the absence of antibiotic therapy or surgical intervention, infective endocarditis is almost always fatal.

Besides the often-rapid deterioration of the heart (and, possibly, other organs), an additional difficulty in managing these patients during surgery is the complex nature and length of the procedure. As was evidenced by results of REFRESH I, procedural length and relative complexity are positively correlated to higher levels of (toxic) plasma free hemoglobin (PfHb). Evidence also indicates that hemolysis (including plasma free hemoglobin) during cardiac surgery is a contributor to postoperative kidney injury. Results of REFRESH I showed that among those patients that underwent valve replacement surgery that lasted between 3 and 4.5 hours (i.e. procedures that were relatively long in duration), there was a statistically significant reduction in plasma free hemoglobin when CytoSorb was used as compared to control (i.e. patients in which CytoSorb was not used).

Relative to this 39-patient case series….many of these patients were in very poor condition; 59% (n=23) were considered 'medical emergencies', while the remaining 41% (n=16) were characterized as 'urgent'. Median and mean EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) of the entire cohort was 12.8 and 26.0, respectively. Higher EuroSCORE II scores are associated with higher risk of mortality, with EuroSCORE II scores of 20 to 40 considered to be at very high risk of death. Among these patients evaluated to be at very high risk of death, only one of the six (17%) died. Meanwhile, among the larger cohort with EuroSCORE II $\leq$ 40, 7% (3 of 29) died.

These mortality rates were compared to a (unrelated) case study involving 149 patients with infective endocarditis undergoing valve replacement surgery. These patients were in relatively better health than those in the CytoSorb cases – with 34% considered 'medical emergencies' (vs. 59% with CytoSorb), 42% 'urgent' (vs. 41% with CytoSorb) and 24% 'elective' (vs. 0% with CytoSorb). Median and mean EuroSCORE II scores were 9.8 (vs. 12.8 with CytoSorb) and 15.8 (vs. 26.0 with CytoSorb). But, despite the predicted lower mortality, 42.9% of EuroSCORE II 20 – 40 patients died, compared to 17% with CytoSorb, and 18.0% of EuroSCORE II $\leq$ 40 patients died, versus 7% with CytoSorb.

The lead investigator of the CytoSorb case series noted meaningful reductions in certain inflammatory mediators, including IL-6 and IL-8, as well as "normalization of lactate and base excess back to preoperative baseline levels within 3 days and hemodynamic stability before, during, and after the operation accompanied by a rapid decrease in need for vasopressors." This (i.e. reduction vasopressor requirements and levels of inflammatory and other risk-related markers) is similar to what was observed in the (unrelated) refractory septic shock study. Interestingly, septic shock is one of the factors most closely associated with risk of mortality in patients with infective endocarditis.[4]

REFRESH I Refresher

As a reminder, REFRESH I was a multi-site 40+-patient randomized study comparing CytoSorb plus standard-of-care (SOC) to SOC alone (1:1) in the reduction of free hemoglobin in patients undergoing elective complex cardiac surgery requiring cardiopulmonary bypass with anticipated duration of more than 180 minutes. 46 patients (23 each arm) were assessed in the safety population while 38 (18 CytoSorb, 20 control) were assessed in the efficacy population.

[4] Olmos C., et al. Contemporary epidemiology and prognosis of septic shock in infective endocarditis. European Heart Journal (2013) 34, 1999–2006

In October 2016 CTSO announced positive **safety-related information** and released additional information on the Q1 call. Both the number of total adverse events as well as number of serious adverse events was similar between the treatment and control arms. While there were two deaths in the CytoSorb group (8.7%), this was not statistically different than the one (4.3%) in the control group. Of the 121 adverse events in the CytoSorb arm, two were related to the device – with both related to a drop in platelets.

	Control (N = 23)	CytoSorb (N = 23)
Total Number AEs	137	121
Total Number SAEs	43	44
Mortality	1 (4.3%)	2 (8.7%)
Device Related AEs		2

SOURCE CytoSorbents

Of the 121 adverse events in the CytoSorb arm, two were related to the device – with both related to a drop in platelets. A decrease in platelets (i.e. cells that help blood clot) is not unexpected given that patients undergoing these procedures must be highly anticoagulated and CPB in itself causes a drop in platelets. The chart below illustrates a drop in platelets in both cohorts even prior to introduction of the CytoSorb therapy in the treatment group. Nonetheless, the platelet level in the CytoSorb arm continues to drop with introduction of that therapy while the control group exhibits more of a leveling off. While the decrease in platelets, per management, was not associated with any serious device-related events and post-op coagulation and bleeding parameters as well as transfusions were not different between the two groups, the greater decrease in platelets among the treatment cohort is something that investigators will look at in more detail.



SOURCE CytoSorbents

REFRESH I Efficacy: CytoSorb More Effectively Reduces PfHB Which Is Associated With Kidney Injury….
A clinical study by Windsant, et al. indicated that hemolysis (including plasma free hemoglobin) during cardiac surgery is a contributor to postoperative kidney injury.[5] Plasma free hemoglobin can be dangerous, particularly at relatively high levels. While levels at or below 60 mg/dL have been found to be generally safe, levels over 120 mg/dL have been associated with acute kidney injury (AKI). As it relates to efficacy, there appears to be an association between the type of cardiac surgery and how much plasma free hemoglobin is generated. Specifically, valve replacement surgery (either in isolation or in combination with other cardiac surgery procedures) appears to be associated with higher levels of plasma free hemoglobin.

The average peak plasma free hemoglobin level of the nine patients in the control group (efficacy population) in REFRESH I that underwent valve replacement surgery was 121 mg/dL (median was 123 mg/dL) – or, at potentially dangerously-high levels.

[5] Iris C. Vermeulen Windsant, et al. Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage. Front Physiol. 2014; 5: 340. Published online 2014 Sep 8. doi: 10.3389/fphys.2014.00340

Control group only: Peak PfHb in Different Surgical Procedures (mg/dL)						
Procedure	N	Mean	Std	Median	Min	Max
All	20	104.0	58.54	101	23	245
Valve Replacement	9	121.0	46.57	123	57	204
Non-valve Replacement	11	90.1	65.60	61	23	246

CPB Length (median control): 2.8h (Valve) vs 4.0h (Non-valve), p=0.03

SOURCE CytoSorbents

Valve replacement patients in the CytoSorb group fared better as it relates to PfHb levels. Among those patients in REFRESH I that underwent valve replacement surgery that lasted between 3 and 4.5 hours, CytoSorb demonstrated a statistically significant reduction in plasma free hemoglobin as compared to control.

CPB Length	Mean Reduction of pfHb (mg/dL)	P-value
3.0	35 mg/dL	0.09
3.5	48 mg/dL	0.05
4.0	61 mg/dL	0.05
4.5	74 mg/dL	0.07

SOURCE CytoSorbents

Interestingly, these findings are similar to an earlier pre-clinical study which found CytoSorb was more effective than standard bypass circuit in reducing free hemoglobin from bovine blood. In fact, the charts from REFRESH (left) and the in vitro bovine-blood study (right) have very similar patterns.





C3a / C5a:
In addition to plasma free hemoglobin, significant reductions in the activated complements C3a and C5a, high levels of which are associated with poor outcomes, were also observed.

In Summary:
Evidence to date has shown;

- high levels of PfHb are generated during cardiac surgery and valve replacement surgery is associated with particularly high levels
- an association between high levels (i.e. > 120 mg/dL) of PfHb and AKI
- CytoSorb's ability to significantly reduce PfHb vs. control in valve replacement procedures (3hr – 4.5hrs)

Refractory Septic Shock Study

Published in September 2017 in the Journal of Artificial Organs, *Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study*[6] (Germany) evaluated the use of CytoSorb

[6] Friesecke S. et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs DOI 10.1007/s10047-017-0967-4

treatment in 20 patients with refractory septic shock. The study assessed the ability of CytoSorb to reduce vasopressor requirements (i.e. life-saving drugs) and improve outcomes (based on organ function, reversal of shock and lower mortality) among a group of critically-ill patients.

Septic shock occurs when infection leads to critically low blood pressure and organ failure. It often results in death. Vasopressors, such as noradrenaline (norepinephrine), dopamine, vasopressin and epinephrine are used to increase blood pressure through methods such as increasing the heart rate and vasoconstriction. Refractory (i.e. critically-ill) septic shock is characterized as persistently-low blood pressure despite vasopressor therapy and adequate fluid resuscitation. As persistently-low blood pressure can lead to multiple organ failure, refractory septic shock patients are at particularly high risk of death.

Patients with refractory shock after six hours of standard treatment were included in the study to receive CytoSorb therapy. Certain criteria related to venous oxygen saturation, fluid administration, cardiac output and organ function were used to determine when standard therapy was no longer effective (at which point CytoSorb therapy was introduced). Patients that received CytoSorb therapy were critically ill, all of which had kidney failure, little or no urine output, respiratory failure (requiring mechanical ventilation) and were on high doses of vasopressors. Based on high severity of organ dysfunction and overall severity of disease (based on SAPS II score), predicted mortality among this cohort was greater than 80%.

Prior to the start of CytoSorb therapy;

- lactate clearance in all patients was very low (<25%) and was zero or negative in 16 of the 20. Lactate level is a marker for cellular hypoxia (increasing clearance indicates increasing oxygen saturation) and is positively correlated to the risk of mortality. Studies have shown that lactate clearance is an independent predictor of death[7] in sepsis patients and lactate clearance of less than 33% over 12 hours is associated with a mortality rate of 97%
- average Simplified Acute Physiology Score (SAPS II) implied risk of death of at least 80%
- vasopressor (noradrenaline) demand was increasing in all 20 patients in the two hours prior to commencement of CytoSorb therapy
- IL-6 levels were very high. Average IL-6 among all patients was 25,523 pg/mL, indicative of cytokine storm

Primary endpoint was the change in noradrenaline requirement after six hours and after twelve hours of CytoSorb treatment as compared to baseline (i.e. just prior to the introduction of CytoSorb therapy). Secondary endpoints included resolution of shock and lactate clearance. Change in IL-6 was used as the determinant as to whether CytoSorb would be discontinued. If no further change in IL-6 was expected, then CytoSorb treatment was ended.

Results;

- Primary endpoint: noradrenaline requirements were significantly reduced after both six ($p=0.03$) and twelve ($p=0.001$) hours of CytoSorb treatment versus baseline. The decrease continued after 24 ($p<0.001$) and 36 hours ($p<0.001$). (see chart below)
- Secondary endpoints:
    - as compared to the six hours prior to the commencement of CytoSorb treatment, lactate clearance increased significantly with CytoSorb treatment during three (i.e. hour 6–12, hour 12-18 and hour 18-24) of the four (hour 0-6 was also measured but not statistically significant) timepoints measured (see chart below)
    - shock reversal was achieved in 13 patients, although four of these patients died later of other causes. Nine patients survived 28 days (i.e. standard, accepted primary endpoint in pivotal sepsis studies). This 45% survival compares very favorably to the 20% or less survival rate as predicted by SOFA, SAPS III and lactate clearance metrics of the patients prior to the start of CytoSorb therapy
- In fourteen patients IL-6 levels were either reduced by 90% (or more) or IL-6 concentration was reduced to less than 500 pg/ml

[7] Philippe M. et al. Lactate clearance for death prediction in severe sepsis or septic shock patients during the first 24 hours in Intensive Care Unit: an observational study. Ann Intensive Care. 2013; 3: 3.

Primary Endpoint: Significant Reduction in Vasopressors



Fig. 1 Noradrenaline dose before and during treatment with CytoSorb®. Values are shown as means with 95% CIs. Difference vs. "hour 0" (CytoSorb® start): $*p < 0.05$, $**p < 0.01$, $***p < 0.001$. Initial and start $n = 20$, hour 6, 12 and 18 $n = 19$, hour 24 $n = 18$

SOURCE: Frisecke S., et al

Secondary Endpt: Significant Increase in Lactate Clearance



Fig. 2 Lactate clearance before and during treatment with CytoSorb®. Values are shown as means with 95% CIs. Difference vs. "hour -6 - 0" (6 h before CytoSorb® start): $*p < 0.05$, $***p < 0.001$, *n.s.* not significant

SOURCE: Frisecke S., et al.

While this study is too small and not designed or powered to evaluate efficacy on clinical outcomes, we do think it adds to the growing evidence supporting the relationship between the reduction of certain inflammatory mediators, such as IL-6, and improved biological functioning. The study further supports the association between controlling cytokine levels and pared risk of cellular hypoxia, organ failure, hypotension and other signs of hemodynamic instability associated with sepsis and mortality. But it takes this relationship another important step forward, demonstrating that cytokine elimination (via CytoSorb) may provide significant incremental benefit to outcomes and survival in patients with refractory septic shock in which the benefits of vasopressor therapy have been exhausted and predicted mortality may otherwise be near 100%.

Sepsis is a complex condition, the pathogenesis of which is influenced by a number of factors but is still not fully understood. Compounding the difficulty in treating the condition is that even slight patient-to-patient differences (age, health, co-morbidities, etc) may play a significant role in the body's response and in clinical outcomes. This heterogeneity makes trial design a major challenge and means pursuit of a sepsis indication is a risky endeavor (as evidenced by the high failure rate of various other sepsis therapy candidates) and possibly a costly mistake.

Given these challenges, CytoSorbents has been methodical in evaluating possible options as it relates to designing a clinical program around sepsis. Chipping away at the heterogeneity through narrowing of patient and/or condition-related differences and which will help power response to CytoSorb therapy is clearly a goal and one that should improve the chances of success (or at least reduce risk of failure). Results of this refractory sepsis study, like ones that came before and others that will certainly come in the future, should help the company in making informed decisions relative to how best to proceed relative to a pivotal sepsis clinical program.

Cytokine Release Syndrome Associated With CAR-T Cell Cancer Therapies

The feasibility of CytoSorb as a treatment for cytokine release syndrome (CRS) could soon become more clear given the recent FDA approvals of two CAR-T immunotherapies; Novartis' Kymriah (tisagenlecleucel-T) and Gilead/Kite's Yescarta (axicabtagene ciloleucel). These novel CAR-T therapies have shown extraordinary efficacy in the treatment of certain cancers but have also been associated with certain severe side effects in some patients. Specifically, clinical studies have shown that severe CRS (i.e. severe inflammatory response with excessive and harmful levels of cytokines) effects about 47% of patients treated with these therapies. CRS can result in serious complications and lead to organ failure and death.

While corticosteroids and tocilizumab have been used with some success in controlling CRS, there are drawbacks. This includes that corticosteroids are suspected of potentially comprising immunotherapy efficacy. Relative to tocilizumab, researchers have noted that its use should be avoided if macrophage activating syndrome (MAS) is suspected.[8] Interestingly, CytoSorb has been used successfully in several patients with a condition called

[8] Shannon L. Maude, MD, PhD,* David Barrett, MD, PhD,* David T. Teachey, MD,* and Stephan A. Grupp, MD, PhD. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies. Cancer J. 2014 Mar-Apr; 20(2): 119 122.

hemophagocytic lymphohistiocytosis (HLH) - one of these was the subject of a case report published in early March 2017 in the Journal of Clinical Immunology. Studies have shown that subjects with secondary HLH, which is often caused by virologic infection and characterized by a strong and sometimes uncontrollable immune response including CRS, can exhibit responses similar to cancer patients treated with certain immunotherapies. The similarity in CRS response in HLH and cancer patients treated with immunotherapies and CytoSorb's early success in treating HLH patients (via reduction in inflammatory markers) is encouraging, particularly as it may relate to mitigating the toxicity of CAR-T therapies. Another factor that could play in CTSO's favor is the fact that Dr. June Carter, who recently joined CytoSorbents' scientific advisory board, also led the CTL019 (i.e. Kymriah) program at the University of Pennsylvania.

Novartis and Gilead are also seeking approval in Europe, which could come in short-order. At that point, CytoSorb could be employed to treat CRS. CTSO would likely pursue investigator-initiated studies overseas, as they have done with other indications, in order to build the experience database – which, assuming positive results, could drive adoption of CytoSorb for CRS. Given the extraordinary efficacy already seen with these two initial therapies and the recent and growing massive inflow of investment dollars targeting immunotherapy development, this is an application that we

HISTORICAL STOCK PRICE

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brian Marckx, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.